ADTX ADiTx Therapeutics Inc.

2.37
-0.1  -4%
Previous Close 2.47
Open 2.46
52 Week Low 1.62
52 Week High 9.58
Market Cap $29,102,870
Shares 12,279,692
Float 10,457,167
Enterprise Value $16,579,321
Volume 770,081
Av. Daily Volume 1,198,784
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
ADi
Psoriasis
Phase 1/2
Phase 1/2
Phase 1/2 trial planned.

Latest News

  1. Service Availability is Expected in January 2021

    MOUNTAIN VIEW, CA and REHOVOT, ISRAEL, Dec. 14, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, and Todos Medical Ltd. (OTCQB:TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer's disease, today announced the signing of a distribution agreement for AditxtScore™ for COVID-19, with planned availability in January 2021. 

    Todos Medical…

    Service Availability is Expected in January 2021

    MOUNTAIN VIEW, CA and REHOVOT, ISRAEL, Dec. 14, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, and Todos Medical Ltd. (OTCQB:TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer's disease, today announced the signing of a distribution agreement for AditxtScore™ for COVID-19, with planned availability in January 2021. 

    Todos Medical has secured the rights to distribute AditxtScore™ for COVID-19 to monitor immunity against SARS-CoV-2. Blood samples will be collected by Todos and/or its network of partners and sent to Aditxt's CLIA accredited AditxtScore™ Center for processing. 

    Amro Albanna, Co-founder and CEO of Aditxt, commented, "This agreement marks a milestone for AditxtScore™ and Aditxt as a whole. Todos Medical is Aditxt's first commercial customer for our proprietary AditxtScore™ immune monitoring platform and its first application, AditxtScore™ for COVID-19. As the availability of COVID-19 vaccines increases, the need to understand an individual's immune profile to measure its effectiveness, increases as well. We look forward to working with the team at Todos and providing our innovative AditxtScore™ platform as a complement to the suite of testing solutions that they offer."

    Gerald Commissiong, President and CEO of Todos Medical, added, "After a thorough review of the immune-related COVID-19 testing market, we believe that Aditxt's platform technology represents a unique multidimensional view of the immune system that will be critical to allow physicians and scientists to categorize immune responses to vaccines and therapeutic approaches for COVID-19 in order to determine which interventions to use for which patients in a personalized way. As vaccines for COVID-19 are rolled out, it is imperative that we evaluate patients' immune status prior to and after vaccination, and track when immunity is gained and how long it might last with repeat immune testing. The AditxtScore™ for COVID-19 scoring system will initially include antibody and neutralizing antibodies, and will soon include T-cell and B-cell responses as well, which makes it the most comprehensive immune profiling tool for COVID-19 available in the market."

    About Aditx Therapeutics

    Aditxt is developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring biotechnology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming biotechnology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com and www.aditxtscore.com

    About Todos Medical Ltd.

    Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB:TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. For more information, please visit https://www.todosmedical.com/.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    Aditxt Investor Relations:

    PCG Advisory

    Jeff Ramson

    Chief Executive Officer

    646-863-6341

    Todos Investor Relations:

    Kim Sutton Golodetz

    LHA Investor Relations

    Senior Vice President

    (212) 838-3777

    Todos Corporate Contact:

    Priyanka Misra

    Todos Medical

    (917) 983-4229 ext. 103



    Primary Logo

    View Full Article Hide Full Article
  2. To Indicate Interest in a Personal AditxtScore™ for COVID-19, Visit AditxtScore.com 

    MOUNTAIN VIEW, CA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that physician and media personality Dr. Drew Pinsky, a senior advisor to Aditxt, and Aditxt CEO Amro Albanna, will review the data generated from each of their AdixtScore™ for COVID-19 results. The results will become part of Aditxt's on-going clinical study that measures the level and durability of immunity against COVID-19.

    The AditxtEngage™…

    To Indicate Interest in a Personal AditxtScore™ for COVID-19, Visit AditxtScore.com 

    MOUNTAIN VIEW, CA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that physician and media personality Dr. Drew Pinsky, a senior advisor to Aditxt, and Aditxt CEO Amro Albanna, will review the data generated from each of their AdixtScore™ for COVID-19 results. The results will become part of Aditxt's on-going clinical study that measures the level and durability of immunity against COVID-19.

    The AditxtEngage™ event will be held on Tuesday, December 1, 2020 at 10:00 am ET. The event will be streamed live from the AditxtScore™ Center in Richmond, VA, and will include Q&A from the audience. The event can be accessed by following the registration link below or through Dr. Drew's website at www.DrDrew.com/live

    To register, please go to: 

    https://us02web.zoom.us/webinar/register/WN_UsDB8qtUTkm1JUZvFZ5A9Q

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Relations:

    PCG Advisory

    Jeff Ramson

    Chief Executive Officer



    646-762-4518

    www.aditxt.com

    



    Primary Logo

    View Full Article Hide Full Article
  3. Voorhies has Extensive Business and Industry Experience in Diagnostics & Monitoring  

    Mountain View, CA, Nov. 20, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Anthony Voorhies as Head of Business Development for AditxtScore™.

    Mr. Voorhies has commercialized a broad range of diagnostic tools, biomarkers, and FDA-cleared imaging and functional testing medical devices and has collaborated with some of the world's preeminent research institutions, conducting training for research…

    Voorhies has Extensive Business and Industry Experience in Diagnostics & Monitoring  

    Mountain View, CA, Nov. 20, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Anthony Voorhies as Head of Business Development for AditxtScore™.

    Mr. Voorhies has commercialized a broad range of diagnostic tools, biomarkers, and FDA-cleared imaging and functional testing medical devices and has collaborated with some of the world's preeminent research institutions, conducting training for research protocols and introducing complementary diagnostics into clinical care models. He has spent over a decade building and managing high performance teams in the health sciences industry, growing them from early stage to high-growth performance. Prior to joining Aditxt, Anthony helped deploy medical device, diagnostics, and COVID-19 strategies for Calroy Health Sciences LLC, and previously was the U.S. Product Director for Itamar Medical, Inc.

    Amro Albanna, Co-Founder and CEO of Aditxt, commented, "AditxtScore is well-positioned for growth and Anthony is the right leader to move the opportunity forward. He has the extensive business and industry background that's needed to launch and grow the AditxtScore™ platform as an immune monitoring service and shares our vision for the platform's potential to transform immune diagnosis from reactive testing to proactive monitoring. We welcome him to our Aditxt family and look forward to realizing that vision together."

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



    Investor Relations:

    PCG Advisory

    Jeff Ramson

    Chief Executive Officer



    646-762-4518

    www.aditxt.com



    Primary Logo

    View Full Article Hide Full Article
  4. Upcoming Vaccines Increase the Need for Ongoing Monitoring of Presence and Durability of Immunity

    Mountain View, CA , Nov. 19, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that its AditxtScore™laboratory operations for immune monitoring has secured CLIA certification, allowing for the launch of AditxtScore™for COVID-19 as a Laboratory Developed Test (LDT).

    AditxtScore's™ operations will initially be co-located at the facilities of Salveo Diagnostics, Inc., the Company's collaboration partner, located…

    Upcoming Vaccines Increase the Need for Ongoing Monitoring of Presence and Durability of Immunity

    Mountain View, CA , Nov. 19, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that its AditxtScore™laboratory operations for immune monitoring has secured CLIA certification, allowing for the launch of AditxtScore™for COVID-19 as a Laboratory Developed Test (LDT).

    AditxtScore's™ operations will initially be co-located at the facilities of Salveo Diagnostics, Inc., the Company's collaboration partner, located in Richmond, VA.  This will expedite the commercial launch of AditxtScore™ for COVID-19, which is targeted for January 2021. These Company-managed AditxtScore™operations will provide Aditxt with the necessary flexibility, stringent quality control and rapid deployment needed for these sensitive products. 

    In parallel, Aditxt plans to continue to pursue the EUA application it submitted to the Food and Drug Administration in late August 2020 for AditxtScore™for COVID-19, which is expected to provide a path to 510(k) clearance as well. 

    Amro Albanna, Co-Founder and CEO of Aditxt, commented, "As we prepare to roll out the AditxtScore™ immune monitoring platform and applications, the establishment of our own CLIA-certified AditxtScore™ operation is vital to realizing our full vision, which is to transform immune diagnosis from reactive testing to proactive monitoring. We believe that the upcoming availability of two new vaccines, as was recently announced, will increase the need for ongoing monitoring of the immune system in order to assess the presence and durability of immunity at any point in time." 

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



    Investor Relations:

    PCG Advisory

    Jeff Ramson

    Chief Executive Officer



    646-762-4518

    www.aditxt.com



    Primary Logo

    View Full Article Hide Full Article
  5. Mountain View, CA, Nov. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today provided a business update in conjunction with the filing of its Form 10-Q with the Securities and Exchange Commission.

    Amro Albanna, Co-Founder and CEO of Aditxt, commented, "It's been an exciting quarter for Aditxt that started with our successful IPO and Nasdaq listing in early July, followed several weeks later by a successful follow-on public offering. During the quarter we also added well-known industry names to our team and advisory…

    Mountain View, CA, Nov. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today provided a business update in conjunction with the filing of its Form 10-Q with the Securities and Exchange Commission.

    Amro Albanna, Co-Founder and CEO of Aditxt, commented, "It's been an exciting quarter for Aditxt that started with our successful IPO and Nasdaq listing in early July, followed several weeks later by a successful follow-on public offering. During the quarter we also added well-known industry names to our team and advisory board. Most importantly, we introduced the first application of our AditxtScore™ Monitoring platform, AditxtScore™ for COVID-19, for use in detecting antibodies against SARS-CoV-2 antigens, and for which we are awaiting a response from the U.S. Food and Drug Administration regarding the Emergency Use Authorization (EUA) application that we filed in August. As we've announced, we're working hard to position the Company for commercialization of this product. We believe that Aditxt has accomplished much during its first quarter as a public company, and with cash of $13.7 million at September 30th to support the execution of our strategy, we are well positioned to achieve our goals for growth."

    For Aditxt's complete financial results for the period ended September 30, 2020, see the Company's quarterly report on Form 10-Q that was filed with the Securities and Exchange Commission on November 13, 2020. 

    About Aditx Therapeutics



    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



    Investor Relations:

    PCG Advisory

    Jeff Ramson

    Chief Executive Officer



    646-762-4518

    www.aditxt.com

    Primary Logo

    View Full Article Hide Full Article
View All ADiTx Therapeutics Inc. News